Research programme: xenotransplantation - Infigen/Novartis
Latest Information Update: 24 Apr 2003
At a glance
- Originator Infigen; Novartis
- Mechanism of Action Tissue replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Xenotransplant rejection
Most Recent Events
- 20 Mar 2001 Preclinical development for Xenotransplant rejection in USA (Unknown route)